SCM
CERE

Segantii Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Segantii Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$48.3M Buy
1,143,426
+548,907
+92% +$23.1M 3.15% 10
2023
Q4 		$25.2M Buy
+594,519
New +$17.1M 1.32% 21

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Segantii Capital Management's CERE Position: Q1 2024 in Review

Segantii Capital Management increased its Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) stake by 92% in Q1 2024, buying an estimated $23.1M and bringing the position to 1,143,426 shares worth $48.3M. The position accounts for 3.15% of the portfolio, ranked #10.

Segantii Capital Management first reported a position in CERE in Q4 2023 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • Segantii Capital Management held 1,143,426 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $48.3M as of Q1 2024.
  • Segantii Capital Management bought 548,907 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $23.1M.
  • Cerevel Therapeutics Holdings, Inc. Common Stock made up 3.15% of Segantii Capital Management's portfolio in Q1 2024, its #10 holding.
  • Segantii Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Segantii Capital Management's 13F filing for Q1 2024, filed 14 May 2024.